about
Dissecting the Potential Interplay of DEK Functions in Inflammation and CancerSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewBaseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysisA Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Dapagliflozin for the treatment of type 2 diabetes: a review of the literatureEfficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.Clinical implication of SGLT2 inhibitors in type 2 diabetes.Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.A concise and practical stereoselective synthesis of ipragliflozin L-proline.Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C-MDG.Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans.A Review about Regulatory Status and Recent Patents of Pharmaceutical Co-Crystals
P2860
Q26783559-B7D103EC-E601-48B6-8D20-147E287335C1Q28079134-20BCDDCF-4D06-43FA-B66E-BFA3573B898DQ31117903-124E1F29-60E2-412D-A5DF-00CC25BA3D0DQ33767478-1E5FEF58-68AC-46B0-8563-59ABB1E0FFECQ34161881-60492868-3985-4C6D-B63E-557EBC534553Q34710819-245B42DC-3A70-4790-A027-4CDE10ADDF90Q36843902-A2C9FF96-155D-4639-AD3F-07C80F4CE275Q37421058-AA39673A-465D-48B1-AD2B-F7483D33480FQ38221980-F308F7A1-EFE0-45B7-83CC-10FB7353E601Q38330456-C042ACDD-0DA0-4EFB-BF4E-5F87A36D27ECQ38340949-5E2A4612-9A55-463C-AEC1-AC2E9BA796ABQ38389823-475B1B76-FB56-4988-A171-64999F4C1D2DQ38669170-E7091A96-343B-4E14-B669-89EEAB1E6FEBQ38783203-EDDEDFB8-BF13-41D3-AA33-6FD4DCE52FABQ38863649-21C67AA5-186A-4367-99B5-F24503EF641EQ38908779-BFA4F287-116B-42C8-BFE9-C42140585D10Q41070264-51EB57A0-7B20-4509-9FB3-5B8BD7277F85Q41762575-BC1D9417-720A-4205-9D4F-BDF7B77F69BBQ47398293-5C72B896-E2FA-4681-804B-D6756E703213Q51291939-5ED900C6-4A7B-4ED5-84FE-143A79505BBCQ51679305-2CDFFD57-EB83-4EA3-B9A0-92DB504B7465Q57136283-D90381CC-117B-4751-806B-33DC37905195
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Ipragliflozin: first global approval.
@ast
Ipragliflozin: first global approval.
@en
Ipragliflozin: first global approval.
@nl
type
label
Ipragliflozin: first global approval.
@ast
Ipragliflozin: first global approval.
@en
Ipragliflozin: first global approval.
@nl
prefLabel
Ipragliflozin: first global approval.
@ast
Ipragliflozin: first global approval.
@en
Ipragliflozin: first global approval.
@nl
P1433
P1476
Ipragliflozin: first global approval.
@en
P2093
Raewyn M Poole
Rosselle T Dungo
P2888
P304
P356
10.1007/S40265-014-0204-X
P577
2014-04-01T00:00:00Z
P6179
1001075506